id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-005478-5iu38pr6	nan	The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Oral Session	2019-07-03		.txt	text/plain	63350	3869	58	There were some differences among groups: patients in group-1 were younger (median age 46 years, p< 0.02) were transplanted in more recent year (2015, p< 0.001), received more frequently a regimen based on TBF (thiotepa, fludarabine and busulfan) (83%, p< 0.001) and bone marrow (BM) as source of stem cells (77%, p< 0.001), with no ATG (100%, p< 0.001). Clinical Trial Registry: NCT01217723 Disclosure: None of the Authors have any conflicts of interest to declare O105 Immune reconstitution -based score at diagnosis of CGVHD predicts GVHD severity and overall-survival: A novel prognostication tool for GVHD treatment tailoring Background: Allogeneic stem cell transplantation (HSCT) survivors are at a relevant risk of developing chronic GvHD (cGvHD), which importantly affects quality of life and increases morbidity and mortality.	./cache/cord-005478-5iu38pr6.txt	./txt/cord-005478-5iu38pr6.txt